News|Videos|November 20, 2026

Mary Jane Minkin, MD, unpacks hormone therapy myths

Fact checked by: Benjamin P. Saylor

Hormone therapy does not cause weight gain, according to Mary Jane Minkin, MD, FACOG, and age at initiation shapes cardiovascular risk in menopause.

Estrogen remains widely misunderstood among clinicians who prescribe hormone therapy, according to Mary Jane Minkin, MD, FACOG, in part because of how the Women’s Health Initiative (WHI) is interpreted. Minkin, speaking with Contemporary OB/GYN at The Menopause Society 2026 Annual Meeting, notes that the WHI evaluates only 1 estrogen-progestin combination and 1 estrogen-alone regimen, whereas the past 20 to 30 years have brought substantial advances in both estrogens and progestogens, with data showing that not all estrogens carry the same risks.

Route of administration is 1 example. Oral estrogen is associated with a slightly increased risk of blood clots, but transdermal estrogen is not, Minkin says. Women with a uterus need a progesterone or progestin, yet many clinicians are not taught about the range of progesterone and progestin delivery systems now available.

Hormone therapy does not cause weight gain, which even the WHI shows, Minkin says. Minkin coauthors an analysis of the phase 3 REPLENISH trial that examines weight and blood pressure with combined 17β-estradiol and progesterone.¹ She does not characterize hormone therapy as a weight-loss treatment, but says some women lose weight because estrogen and progesterone improve their sleep, and better sleep supports weight loss.

“I’m not going to give you extra weight by giving you estrogen. I might help as far as getting you some sleep,” Minkin says of her patient counseling.

Supplements warrant similar nuance. Herbal products and nutritional supplements in the United States lack the regulatory oversight found in other countries, Minkin explains. In Germany, for example, herbal products must pass certain tests before reaching the market. Her own research focuses on Remifemin, a German black cohosh product, and she discloses that she consults for the company. Black cohosh products have been associated with liver damage and abnormal liver function tests, but trials using this specific product show no association with abnormal liver function tests, Minkin says. Liver risk therefore depends on the specific product.

Age is central to the relationship between estrogen and cardiovascular health. A reanalysis of WHI data released about 1 year ago evaluates women with hot flashes by age group.² Among women aged 50 to 59 years, there is no increased cardiovascular risk, consistent with the Menopause Society’s recommendation that estrogen therapy is safe from a cardiovascular standpoint in women within 10 years of their last menstrual period or younger than 60 years. Women aged 60 to 69 years do not fare poorly but do not necessarily fare well, whereas women aged 70 to 79 years with hot flashes show an increased risk of cardiovascular disease. Initiation in that oldest group should be limited to very rare circumstances, according to Minkin.

“On a routine basis, we would not encourage women 70 to 79 to think about initiating hormone therapy,” she says.

REFERENCES

1. Black DR, Minkin MJ, Graham S, et al. Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial. Menopause. 2021;28(1):32-39. doi:10.1097/GME.0000000000001659

2. Rossouw JE, Aragaki AK, Manson JE, et al. Menopausal hormone therapy and cardiovascular diseases in women with vasomotor symptoms: a secondary analysis of the Women’s Health Initiative randomized clinical trials. JAMA Intern Med. 2025;185(11):1330-1339. doi:10.1001/jamainternmed.2025.4510


Related to this article